AI Robotics in Medicine
PublicTracking updates in AI Robotics in the healthcare industry
XRPHAI price prints diverge as 68k-pharmacy reach touted
Sunday, May 24, 2026
XRP Healthcare AI (XRPHAI) shows conflicting price prints across exchange pages and a listed £8. 44M fully diluted valuation on a 1B supply, while circulating supply remains undisclosed.
That market noise contrasts with the project’s pitch: an AI health app tied to prescription savings across 68,000+ U.S. pharmacies and a token rewarding verified healthcare engagement.
Watch for resolution of pricing discrepancies and clearer float data versus the scale of the claimed real-world footprint.
Tracking: Medicine Robotics · AI Medicine · AI Healthcare
1. XRP Healthcare AI token shows sharp swings; platform touts 68,000-pharmacy reach
XRP Healthcare AI (XRPHAI), described as the first AI healthcare platform on the XRP Ledger, posted conflicting price prints across exchange pages. One page lists 1 XRPHAI at £0.
00625 with a 12. 08% daily drop, while another shows ₦10.
33 with a 21. 56% decline, and a third cites ₦12.
38 alongside a 5. 83% gain.
A separate page pegs the token near £0. 00844 and indicates a £8.
44M fully diluted valuation on a 1B total supply, with circulating supply undisclosed.
Beyond the price noise, the project markets an AI-powered app linking users to digital health tools and prescription savings across 68,000+ U.S. pharmacies, including CVS, Walgreens, and Walmart.
The XRPHAI utility token is used to reward verified healthcare engagement globally, tying token incentives to claimed real-world healthcare use.
Key facts:
- Pages show daily changes of -12.08%, -21.56%, and +5.83% for XRPHAI.
- Quoted prices range from £0.00625–£0.00844 and ₦10.33–₦12.38 per token.
- FDV is listed at £8.44M on a 1B total supply; circulating supply is undisclosed.
Why it matters: If the app’s pharmacy savings and engagement-reward model deliver at scale, U.S. consumers could benefit from lower out-of-pocket costs and improved adherence.
But inconsistent pricing data and an undisclosed circulating supply complicate valuation and risk; credibility will hinge on consistent market metrics and verifiable integrations with the named pharmacy networks.